NCT06477055Completed
The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
A Multicenter, Real-World, Observational Study: Genomic Landscape of Recurrence in Early-Stage (Clinical Stage IB-IIIA) Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Sensitizing Mutations After Adjuvant Osimertinib Treatment
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
This study was a multicenter, real-world observational study aimed at characterizing the genomic landscape of recurrence in patients with EGFR-sensitizing mutation-positive early-stage (clinical stage IB-IIIA) non-small cell lung cancer who received adjuvant osimertinib after surgery.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 43 (actual)
- First submitted
- 19 Jun 2024
- Start date
- 2 Dec 2025
- Primary completion date
- 21 Apr 2026
- Lead sponsor
- Hunan Province Tumor Hospital
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT06477055
What you commit to
- Study type: Observational
- Participants enrolled: 43
- From 2 Dec 2025 to the primary completion date, 21 Apr 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with stage I-III NSCLC whose surgical resection cannot be confirmed;
- Received adjuvant therapy other than that specified in the ADAURA study;
Other illness
- History of other malignant tumors within 2 years;
Lab values
- Patients assessed by the investigator as unfit for enrollment, such as neurological disorders or metabolic disorders, physical examination or laboratory examination suspected that the patient has a possible disease, or has treatment-related complications High risk etc.
Other
- No NGS test report at recurrence;
Who the study is looking for
- Informed consent signed;
- Age ≥ 18 years;
- Histologically confirmed diagnosis of non-squamous non-small cell lung cancer;
- Patients with stage IB-IIIA (TNM 8#) NSCLC undergo confirmed radical R0 resection;
- Confirmed EGFR sensitive-mutations (exon 19 deletions, 21 L858R point mutations) prior to adjuvant osimertinib therapy;
- Recurrence after/on Osimertinib treatment according to RECIST 1.1;
- NGS gene test report (tumor or blood sample) at the time of recurrence;
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hunan Provincal Tumor Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
| The Second Affiliated Hospital Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.